Pegylated interferon alfa-2a
| Pegylated interferon alfa-2a
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | L03 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | ? |
Pegylated interferon alfa-2a (40kD) (commercial name PEGASYS) is an antiviral drug discovered at the pharmaceutical company F.Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system.
This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.
See also
External links
- Interferon and hepatitis c at pegasys.com
- PMPRB at pmprb-cepmb.gc.ca
- Chemical structure at hepalife.com
- MeSH Pegasys
Cytokines: interferons | |
|---|---|
| Interferon type I | alpha (Pegylated interferon alfa-2a - Pegylated interferon alfa-2b), beta (Interferon beta-1a - Interferon beta-1b) |
| Interferon type II | Interferon-gamma |
| Interferon type III | Interleukin 28 - Interleukin 29 |
Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added
Pictures
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
